Director Rowe bought 1,439,005 shares (1.44M) for $96,098.34 at $0.07 blended on 2025-03-17; cluster of 7 other insiders buying in past 14 days
Rowe purchased 1,439,005 shares across 6 separate transactions on 2025-03-17 at a blended average of $0.07, increasing his total holdings by 523.3% to 1,714,005 shares. This substantial accumulation occurs as part of a cluster pattern: 7 other insiders also bought within the past 14 days. The timing is notable given the stock's weakness—trading at $0.10 currently, down 44.4% from its 52-week high of $0.18 and down 18.6% over the past 30 days. Zomedica remains unprofitable with net income of $-6.7M against quarterly revenue of $7.0M, which contextualizes both the depressed share price and the multi-insider buying activity within a period of stock pressure.